Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks

Inclusion criteria: 1. Males and females with age of 18 to 55 years 2. Age of migraine onset ˂ 50 years 3. Having a diagnosis of migraine according to the International Classification of Headache Disorders 3rd edition (ICHD-3) for at least one year 4. Having a history of 2-8 attacks per month 5. Remaining stable on prophylactic medication (if used) during the 2 months prior to screening and throughout the study period 6. Using effective contraception by the women of childbearing potential during the study 7. Ability to provide written, informed consent and to be compliant with the schedule of protocol assessments Exclusion criteria: 1. Having a diagnosis of other primary (cluster and tension) and secondary headache disorders 2. Having a history of chronic migraine headache 3. History of resistant or refractory migraine headaches based on European Headache Federation consensus 4. Receiving any abortive medication for the treatment of migraine within 48 hours before using Canvert-M 5. History of psychiatric and neurologic disorders (except migraine) or any medical comorbid conditions that interfere with the study results 6. History of nasal sensitivity or allergy to menthol, lavender, rosemary, eucalyptus, wintergreen and basil oil 7. The presence of any skin lesions in the areas where the product is used 8. Treatment with any investigational agent within 30 days prior to screening 9. History of substance use disorders 10. Nursing mothers, pregnant women, and women who plan to become pregnant during the study period 11. Taking carbamazepine, cilostazol, citalopram, clarithromycin, clobazam, colchicine, cyclosporine, digoxin, itraconazole, phenobarbital, phenytoin, rifampin, sirolimus, tacrolimus, tizanidine, and warfarin within 14 days of the study procedure